Venlafaxine extended release - Sun Pharma Advanced Research Company

Drug Profile

Venlafaxine extended release - Sun Pharma Advanced Research Company

Latest Information Update: 23 Apr 2015

Price : $50

At a glance

  • Originator Sun Pharma Advanced Research Company
  • Class Antidepressants; Anxiolytics; Cyclohexanols; Dimethylamines; Small molecules
  • Mechanism of Action Adrenergic uptake inhibitors; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Depressive disorders

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 01 Mar 2014 Preregistration for Depressive disorders in USA (PO)
  • 17 Dec 2013 Sun Pharma Advanced Research Company received complete response letter from the US FDA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top